Gian Paolo Fadini Selected Research

Dipeptidyl-Peptidase IV Inhibitors

9/2021	Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies.
1/2021	Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world.
10/2020	Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis.
8/2018	Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study.
4/2018	Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions.
1/2018	How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors.
1/2018	Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.
1/2018	The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
1/2018	Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors.
10/2017	Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gian Paolo Fadini Research Topics

Disease

50	Type 2 Diabetes Mellitus (MODY) 08/2022 - 05/2010
20	Body Weight (Weight, Body) 08/2022 - 01/2014
13	Insulin Resistance 02/2019 - 08/2007
11	Cardiovascular Diseases (Cardiovascular Disease) 11/2021 - 09/2013
10	Hypoglycemia (Reactive Hypoglycemia) 08/2022 - 06/2009
9	Heart Failure 01/2022 - 09/2015
8	Inflammation (Inflammations) 01/2022 - 03/2008
8	Atherosclerosis 11/2020 - 09/2006
7	Hyperglycemia 07/2022 - 03/2006
7	Ischemia 01/2022 - 03/2010
7	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2015 - 04/2010
6	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2022 - 01/2017
6	COVID-19 06/2022 - 10/2020
6	Diabetes Complications 12/2020 - 06/2009
5	Myocardial Infarction 01/2022 - 11/2016
5	Stroke (Strokes) 01/2022 - 07/2010
5	Wounds and Injuries (Trauma) 01/2020 - 09/2010
5	Vascular Calcification 02/2016 - 08/2007
4	Infections 01/2022 - 01/2016
4	Weight Loss (Weight Reduction) 10/2020 - 12/2013
4	Hypoxia (Hypoxemia) 11/2019 - 09/2010
4	Peripheral Arterial Disease 08/2018 - 03/2010
4	Ulcer 08/2018 - 03/2010
3	Coma (Comas) 02/2021 - 06/2009
3	Obesity 01/2020 - 10/2015
3	Vascular Diseases (Vascular Disease) 08/2015 - 03/2008
2	Ketosis 11/2021 - 01/2020
2	Fournier Gangrene 11/2021 - 01/2019
2	Neoplasms (Cancer) 04/2021 - 01/2012
2	Hypertension (High Blood Pressure) 01/2020 - 12/2014
2	Overweight 01/2020 - 06/2015
2	Diabetes Mellitus 01/2019 - 04/2017
2	Weight Gain 01/2018 - 01/2014
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2018 - 01/2017
2	Chronic Limb-Threatening Ischemia 04/2017 - 02/2006
2	Hyperinsulinism (Hyperinsulinemia) 01/2010 - 08/2007
2	Lung Diseases (Lung Disease) 09/2007 - 07/2006
1	Thrombotic Microangiopathies 06/2022
1	Superinfection 06/2022

Drug/Important Bio-Agent (IBA)

41	Glucose (Dextrose)FDA LinkGeneric 07/2022 - 06/2009
22	Insulin (Novolin)FDA Link 11/2021 - 08/2007
13	Dipeptidyl-Peptidase IV InhibitorsIBA 09/2021 - 07/2013
12	Glucagon-Like Peptide-1 Receptor AgonistsIBA 11/2021 - 01/2018
11	erucylphosphocholineIBA 01/2018 - 05/2005
10	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 01/2017
9	SodiumIBA 11/2021 - 01/2017
8	dapagliflozinIBA 01/2021 - 01/2017
7	Oxygen (Dioxygen)IBA 03/2021 - 01/2005
7	Liraglutide FDA Link 03/2021 - 12/2013
5	omega-Chloroacetophenone (Mace)IBA 01/2021 - 10/2015
5	LipidsIBA 10/2020 - 09/2011
5	EnzymesIBA 02/2019 - 08/2007
5	Hypoglycemic Agents (Hypoglycemics)IBA 01/2018 - 01/2011
5	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2018 - 02/2006
4	SirtuinsIBA 01/2022 - 01/2010
4	Biomarkers (Surrogate Marker)IBA 12/2020 - 09/2006
4	Proteins (Proteins, Gene)FDA Link 02/2019 - 04/2010
4	HDL CholesterolIBA 08/2018 - 08/2014
3	CytokinesIBA 01/2022 - 07/2011
3	Glucagon-Like Peptide-1 ReceptorIBA 11/2021 - 01/2014
3	insulin degludecIBA 03/2021 - 12/2019
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 01/2010
3	LDL CholesterolIBA 01/2021 - 04/2008
3	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021 - 07/2011
3	CholesterolIBA 11/2020 - 01/2017
3	dulaglutideIBA 01/2020 - 01/2020
3	Metformin (Glucophage)FDA LinkGeneric 08/2018 - 09/2015
3	Sirtuin 1IBA 07/2015 - 04/2010
2	IDegLiraIBA 08/2022 - 03/2021
2	ProcalcitoninIBA 06/2022 - 02/2021
2	Streptozocin (Streptozotocin)FDA Link 01/2022 - 09/2010
2	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 10/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 01/2012
2	empagliflozinIBA 04/2021 - 11/2016
2	lixisenatideIBA 03/2021 - 11/2016
2	C-Reactive ProteinIBA 02/2021 - 07/2010
2	InsulinsIBA 12/2020 - 12/2019
2	Pharmaceutical PreparationsIBA 10/2020 - 01/2018
2	Blood Glucose (Blood Sugar)IBA 01/2020 - 07/2019
2	plerixafor FDA Link 01/2020 - 01/2018
2	Exenatide (Byetta)FDA Link 01/2020 - 01/2019
2	Gliclazide (Diamicron)IBA 08/2018 - 01/2018
2	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2018 - 10/2014
2	LinagliptinIBA 10/2017 - 02/2016
2	calcium phosphateIBA 10/2015 - 01/2014
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2015 - 01/2010
2	CalciumIBA 08/2015 - 01/2011
2	NAD (NADH)IBA 07/2015 - 01/2010
2	IncretinsIBA 01/2014 - 09/2011
2	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2010 - 03/2008
1	fibrin fragment D (D-dimer)IBA 06/2022

Therapy/Procedure

23	Therapeutics 03/2021 - 07/2006
5	Glycemic Control 08/2022 - 01/2014
5	Surgical Amputation (Amputations) 11/2021 - 03/2010
3	Hematopoietic Stem Cell Mobilization 01/2020 - 01/2013
2	Critical Care (Surgical Intensive Care) 06/2022 - 01/2022
2	Transplantation 01/2019 - 01/2018
2	Cell- and Tissue-Based Therapy (Cell Therapy) 04/2017 - 03/2010
2	Drug Therapy (Chemotherapy) 07/2013 - 01/2012
1	Length of Stay 06/2022